Publicaciones en colaboración con investigadores/as de Karolinska Institute (23)

2024

  1. Progress in the Treatment of Alzheimer’s Disease Is Needed – Position Statement of European Alzheimer’s Disease Consortium (EADC) Investigators

    Journal of Prevention of Alzheimer's Disease

2023

  1. SIRT2 Inhibition Rescues Neurodegenerative Pathology but Increases Systemic Inflammation in a Transgenic Mouse Model of Alzheimer’s Disease

    Journal of Neuroimmune Pharmacology, Vol. 18, Núm. 3, pp. 529-550

2021

  1. Hypercholesterolemia and 27-Hydroxycholesterol Increase S100A8 and RAGE Expression in the Brain: a Link Between Cholesterol, Alarmins, and Neurodegeneration

    Molecular Neurobiology, Vol. 58, Núm. 12, pp. 6063-6076

2020

  1. Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

    The Lancet Neurology, Vol. 19, Núm. 11, pp. 951-962

  2. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 47, Núm. 8, pp. 1885-1912

2018

  1. Increased Levels of Brain Adrenomedullin in the Neuropathology of Alzheimer’s Disease

    Molecular Neurobiology, Vol. 55, Núm. 6, pp. 5177-5183

2017

  1. Aggregation of the inflammatory s100a8 precedes a? plaque formation in transgenic app mice: Positive feedback for s100a8 and a? productions

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 72, Núm. 3, pp. 319-328

  2. GPR55: A therapeutic target for Parkinson's disease?

    Neuropharmacology, Vol. 125, pp. 319-332

  3. Modulation of BDNF cleavage by plasminogen-activator inhibitor-1 contributes to Alzheimer's neuropathology and cognitive deficits

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1863, Núm. 4, pp. 991-1001

2015

  1. Alterations in brain leptin signalling in spite of unchanged CSF leptin levels in Alzheimer's disease

    Aging Cell, Vol. 14, Núm. 1, pp. 122-129

  2. Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease

    Neuropathology and Applied Neurobiology, Vol. 41, Núm. 4, pp. 471-482

  3. Insufficient Resolution Response in the Hippocampus of a Senescence-Accelerated Mouse Model — SAMP8

    Journal of Molecular Neuroscience, Vol. 55, Núm. 2, pp. 396-405

  4. Sildenafil Decreases BACE1 and Cathepsin B Levels and Reduces APP Amyloidogenic Processing in the SAMP8 Mouse

    Journals of Gerontology - Series A Biological Sciences and Medical Sciences, Vol. 70, Núm. 6, pp. 675-685

2014

  1. The monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model

    Neurobiology of Aging, Vol. 35, Núm. 11, pp. 2603-2616

2013

  1. Is It Possible to Improve Memory Function by Upregulation of the Cholesterol 24S-Hydroxylase (CYP46A1) in the Brain?

    PLoS ONE, Vol. 8, Núm. 7

2012

  1. Combination of apolipoprotein E4 and high carbohydrate diet reduces hippocampal BDNF and Arc levels and impairs memory in young mice

    Journal of Alzheimer's Disease, Vol. 32, Núm. 2, pp. 341-355

2011

  1. Altered expression of neuronal tryptophan hydroxylase-2 mRNA in the dorsal and median raphe nuclei of three genetically modified mouse models relevant to depression and anxiety

    Journal of Chemical Neuroanatomy, Vol. 41, Núm. 4, pp. 227-233

  2. Cholinergic hypofunction impairs memory acquisition possibly through hippocampal Arc and BDNF down regulation

    Hippocampus, Vol. 21, Núm. 9, pp. 999-1009

  3. Dysregulated postsynaptic density and endocytic zone in the amygdala of human heroin and cocaine abusers

    Biological Psychiatry, Vol. 69, Núm. 3, pp. 245-252

2010

  1. Direct involvement of σ-1 receptors in the dopamine D1 receptor-mediated effects of cocaine

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 107, Núm. 43, pp. 18676-18681